International Journal of Environmental Research and Public Health,
Journal Year:
2022,
Volume and Issue:
19(12), P. 7233 - 7233
Published: June 13, 2022
The
need
for
an
anti-COVID-19
booster
dose
posed
organizational
challenge
health
policy
makers
worldwide.
Therefore,
this
study
aimed
to
explore
the
policies
regarding
through
overview
of
recommendations
issued
in
high-income
countries.
Between
10
November
and
16
December
2021,
authors
searched
state-level
official
documents
about
offer
dose,
considering
43
countries
belonging
European
Union
(EU)
or
Organisation
Economic
Co-operation
Development
(OECD).
Mainly
due
lack
English
translation,
15
were
excluded.
A
total
135
selected.
Almost
all
started
administering
between
September
2021.
most
used
products
mRNA
vaccines,
followed
by
Vaxzevria-AstraZeneca
Jcovden-Janssen/Johnson
&
Johnson.
All
established
criteria
define
categories
individuals
be
vaccinated
as
a
priority.
six/five-months
interval
was
main
choice
general
population
with
while
shorter
intervals
chosen
vulnerable
other
vaccines.
Despite
diversities
related
differences
systems,
economical
resources,
numbers,
adapt
these
factors
massive
vaccination
campaign,
progressive
convergence
towards
same
highlighted.
Clinical Infectious Diseases,
Journal Year:
2023,
Volume and Issue:
78(4), P. 889 - 899
Published: Oct. 25, 2023
Abstract
Background
Numerous
prognostic
scores
have
been
published
to
support
risk
stratification
for
patients
with
coronavirus
disease
2019
(COVID-19).
Methods
We
performed
a
systematic
review
identify
the
confirmed
or
clinically
assumed
COVID-19
cases.
An
in-depth
assessment
and
of
bias
(ROB)
analysis
(Prediction
model
Risk
Of
Bias
ASsessment
Tool
[PROBAST])
was
conducted
fulfilling
predefined
criteria
([I]
area
under
curve
[AUC)]
≥
0.75;
[II]
separate
validation
cohort
present;
[III]
training
data
from
multicenter
setting
[≥2
centers];
[IV]
point-scale
scoring
system).
Results
Out
1522
studies
extracted
MEDLINE/Web
Science
(20/02/2023),
we
identified
242
outcome
prognosis
(mortality
109,
severity
116,
hospitalization
14,
long-term
sequelae
3).
Most
were
developed
using
retrospective
(75.2%)
single-center
(57.1%)
cohorts.
Predictor
revealed
primary
use
laboratory
sociodemographic
information
in
mortality
scores.
Forty-nine
included
analysis.
The
results
indicated
heterogeneous
quality
predictor
selection,
only
five
featuring
low
ROB.
Among
those,
based
on
number
heterogeneity
studies,
4C
Mortality
Score
can
be
recommended
clinical
application
so
far.
Conclusions
translation
most
existing
COVID
appear
unreliable.
Guided
development
selection
would
improved
generalizability
may
enhance
pandemic
preparedness
future.
Cell Death Discovery,
Journal Year:
2022,
Volume and Issue:
8(1)
Published: Dec. 15, 2022
The
effects
of
indole-3-carbinol
(I3C)
compound
have
been
described
deeply
as
antitumor
drug
in
multiple
cancers.
Herein,
I3C
was
tested
for
toxicity
and
antiviral
activity
against
SARS-CoV-2
infection.
Antiviral
assessed
vitro
both
VeroE6
cell
line
human
Lung
Organoids
(hLORGs)
where
exhibited
a
direct
anti-SARS-CoV-2
replication
with
an
effect
modulation
the
expression
genes
implicated
innate
immunity
inflammatory
response
observed
at
16.67
μM.
Importantly,
we
further
show
is
also
effective
Omicron
variant.
In
mouse
model,
instead,
possible
through
two
different
routes
administration:
intragastrically
(i.g.)
intraperitoneally
(i.p.).
LD50
(lethal
dose
50%)
values
mice
were
estimated
to
be:
1410
1759
mg/kg
i.g.;
while
i.p.
administration
were:
444.5
375
male
female
mice,
respectively.
Below
these
values,
(in
particular
550
i.g.
250
i.p.)
induces
neither
death,
nor
abnormal
toxic
symptoms
well
no
histopathological
lesions
tissues
analysed.
These
tolerated
doses
are
much
higher
than
those
already
proven
pre-clinical
cancer
models
experiments.
conclusion,
exhibits
significant
activity,
recorded
this
indicated
doses,
characterizing
it
safe
potential
compound.
results
presented
study
could
provide
experimental
data
necessary
start
clinical
trials
treatment
beyond.
Public Health in Practice,
Journal Year:
2023,
Volume and Issue:
5, P. 100368 - 100368
Published: Feb. 10, 2023
To
identify
the
usability
of
telehealth
services
and
barriers
during
coronavirus
disease
(COVID-19)
pandemic
among
healthcare
providers
in
Nineveh
Governorate-Iraq.
This
was
a
multicenter
cross-sectional
survey.
We
collected
required
data
from
April
to
July
2022
using
self-administered
open-ended
questionnaires.
The
were
physicians,
pharmacists,
nurses
with
at
least
six
months
hospitals.
A
modified
form
Telehealth
Usability
Questionnaire
(TUQ)
used
assess
services.
There
460
providers,
which
269/460
(58.5%)
users
These
mostly
physicians
(n
=
167/269,
62.1%),
(52/269,
19.3%),
pharmacists
50/269,
18.6%),
p-value
0.001.
During
COVID-19
pandemic,
100/167,
60.0%)
28/50,
56.0%)
increased
their
provision
Approximately
60%
preferred
provide
synchronized
manner.
participants
smartphones
through
Messenger/Facebook
WhatsApp
applications,
specifically
utilizing
voice
and/or
video
messages.
some
agreement
269)
regarding
overall
mean
score
(±SD)
4.8
(±0.88).
most
reported
poor
Internet
services,
presence
specific
diseases,
lack
technical
comprehension,
insufficient
time
allocated
service.
Healthcare
demonstrated
tendency
towards
Despite
available
barriers,
triage
collaborations
patients,
institutions
are
needed
achieve
more
successful
adoption
these
International Journal of Environmental Research and Public Health,
Journal Year:
2022,
Volume and Issue:
19(12), P. 7233 - 7233
Published: June 13, 2022
The
need
for
an
anti-COVID-19
booster
dose
posed
organizational
challenge
health
policy
makers
worldwide.
Therefore,
this
study
aimed
to
explore
the
policies
regarding
through
overview
of
recommendations
issued
in
high-income
countries.
Between
10
November
and
16
December
2021,
authors
searched
state-level
official
documents
about
offer
dose,
considering
43
countries
belonging
European
Union
(EU)
or
Organisation
Economic
Co-operation
Development
(OECD).
Mainly
due
lack
English
translation,
15
were
excluded.
A
total
135
selected.
Almost
all
started
administering
between
September
2021.
most
used
products
mRNA
vaccines,
followed
by
Vaxzevria-AstraZeneca
Jcovden-Janssen/Johnson
&
Johnson.
All
established
criteria
define
categories
individuals
be
vaccinated
as
a
priority.
six/five-months
interval
was
main
choice
general
population
with
while
shorter
intervals
chosen
vulnerable
other
vaccines.
Despite
diversities
related
differences
systems,
economical
resources,
numbers,
adapt
these
factors
massive
vaccination
campaign,
progressive
convergence
towards
same
highlighted.